|Mr. James R. Howard-Tripp||Exec. Chairman & CEO||270k||N/A||N/A|
|Ms. Leslie Auld MBA, CPA, CA||CFO, Treasurer & Director||150.97k||N/A||N/A|
|Ms. Joanna M. Halsey Esq.||Gen. Counsel, Chief Compliance Officer & HR Director of IDL||165k||N/A||N/A|
|Prof. Choong-Chin Liew Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. David Suria||Sr. Scientist||N/A||N/A||N/A|
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is based in Markham, Canada.
GeneNews Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.